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Introduction
Diffuse gliomas are the most frequent primary brain 
tumors in adults.1 Almost all gliomas relapse despite 
intensive treatment with surgery, radiation, and chemo-
therapy. The most common and most aggressive gliomas, 
glioblastoma (GBM), are isocitrate dehydrogenase (IDH)-
wildtype and classified as 2016 World Health Organization 
(WHO) grade IV. They are characterized by a median over-
all survival that has remained static at around 15 months 
for decades, even in selected clinical trial populations.2–4 
Patients with lower-grade (WHO grade II) IDH-mutated 
gliomas have a more favorable prognosis, but these 
tumors progress and recur as higher grades (III and IV) 
and become resistant to therapy.1 The standard of care 
for diffuse gliomas is maximal safe resection, followed by 
chemoradiation (Fig. 1).5 Patients are then monitored for 
disease progression by imaging at regular intervals fol-
lowing surgery. Evaluation of disease progression is com-
monly guided by specific imaging criteria (eg, Response 
Assessment in Neuro-Oncology [RANO]),6 which rely 
on visual evaluation of contrast enhancement and the 
non-enhancing hyperintense area on T2-weighted imag-
ing. Radiologic features sometimes do not distinguish 
between true tumor progression and its imaging mim-
icker, pseudoprogression, which can result in premature 
withdrawal from a specific treatment or the continuation 
of an ineffective therapy.
Molecular characterization of gliomas has advanced 
our understanding of their genesis7–18 and has identi-
fied somatic alterations that allow their classification 
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Abstract
Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their 
families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the som-
atic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and 
molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic 
abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate 
on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal 
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reveal targetable vulnerabilities and, ultimately, improved outcomes for a patient population in need.
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into subtypes with different biology and median survival 
times.19 This wealth of information has provided a detailed 
molecular portrait of primary glioma. The Cancer Genome 
Atlas (TCGA), which characterized 1100 grades II–IV glio-
mas in detail, has by design focused on untreated tumors. 
The next frontier in glioma genomics is to understand 
recurrent disease, as patients generally die from increas-
ingly resistant tumor regrowth after therapy. Recent pilot 
studies of paired tumors obtained before and after ther-
apy show that there are many differences between the 
primary neoplasm at diagnosis and the recurrent tumor.20 
Progression of gliomas is the result of an evolutionary 
process that involves iterative cycles of clonal expansion, 
genetic diversification, and clonal selection under micro-
environmental pressures, including overcoming antitu-
mor immune responses.21 The presence of multiple cell 
populations with an array of different somatic mutations 
is at least partly responsible for the rapid induction of 
intrinsic resistance to therapy in gliomas.22 Adaptive epi-
genetic and phenotypic responses are equally important. 
The emerging understanding of this dynamic evolution 
of the glioma genome has major implications for cancer 
biology research and potential development of effective 
therapies. This can only be achieved through (i) profiling 
of sufficiently large primary/recurrent patient tumors and 
associated imaging to collect enough patients in order to 
capture low-frequency variants or subtle therapy-driving 
processes and (ii) standardization across biospecimen 
processing and data platforms. Here, we discuss the cur-
rent literature on preliminary molecular longitudinal char-
acterization of gliomas (Table 1) and introduce the Glioma 
Longitudinal Analysis (GLASS) Consortium, which has 
been initiated to establish a definitive portrait of the 
recurrence process and, in doing so, discover vulnerabili-
ties that render the tumor sensitive to therapeutic inter-
vention (Fig. 2).
Molecular Profiling Offers New 
Possibilities for Diagnosis and Therapy 
of Gliomas
Clinical Classification of Adult Diffuse Glioma
Historically, the diagnosis of diffuse gliomas relied purely 
on microscopic evaluation,23 but more recently the com-
bination of histopathology with specific molecular charac-
teristics of gliomas has proven more objective for clinical 
stratification.9,11,17–19,24–29 Gliomas are initially split based 
on the mutation status of the IDH 1 or 2 genes. Tumors 
with wild-type alleles are called IDH-wildtype and 95% 
are GBMs.12 Tumors with IDH mutations are further subdi-
vided based on the presence of complete 1p/19q codele-
tion (IDH mutant codeleted) or tumor suppressor protein 
53 (TP53) mutation and alpha thalassemia/mental retard-
ation syndrome X-linked (ATRX) loss (IDH mutant non-
codeleted).9,11,17,18,24,26–29 Most WHO grades II and III diffuse 
astrocytomas and oligodendrogliomas are IDH mutant and 
contain 1p/19q codeletion. Consensus on how this revised 
molecular classification should be implemented in routine 
clinical practice25 is outlined in the latest WHO 2016 clas-
sification of CNS tumors.19 For the first time, this scheme 
provides data for diagnosis, prognostic grading, and guid-
ing therapeutic decisions.30,31 However, this improved 
classification system is predicated on primary untreated 
disease, and it remains unclear how these molecular mark-
ers impact the biology and prognosis following diagnosis. 
The DNA methylation status of the O6-methylguanine-
DNA methyltransferase (MGMT) gene promoter is pre-
dictive of response to temozolomide therapy in primary 
GBM, and this status appears to be largely stable between 
primary and recurrent disease.32 The value of retesting 
MGMT status after disease progression is debatable, and 
Genomic-based
diagnosis
Evolution of disease with fitness advantage manifest as more aggressive disease
Treatment options adapt to evolving disease using new
biological data to inform treatment choice
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Fig. 1 Usual course of glioma management. GLASS would improve the assessment of gliomas, particularly the prediction of malignant transform-
ation, treatment monitoring, and assessment of tumor alterations noninvasively with imaging and/or liquid biopsies. SMDT (tumor board): specialist 
multidisciplinary team; RT: radiotherapy.
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a methylated MGMT promoter continues to predict treat-
ment response at this stage.
Intratumoral Heterogeneity in Primary Gliomas
Cancer results from a single normal cell that has acquired 
molecular alterations providing it with a growth advantage. 
In glioma, the most frequent somatic abnormalities are 
thought to be founding events.33 This includes somatic muta-
tions in the IDH genes and in the promoter of the telomerase 
reverse transcriptase gene, which is characteristic of IDH-
wildtype GBM as well as IDH-mutant codeleted gliomas.24 
Major aneuploidy, such as 1p/19q codeletion, whole chromo-
some 7 gain, and chromosome 10 loss (IDH-wildtype glio-
mas), are also thought to be glioma-initiating alterations.34–36 
The 3 major glioma subtypes reflect different patient age at 
diagnosis distributions, which further suggests that the 3 
groups represent distinct gliomagenic biologies.
Cancer cell descendants of the same cell of origin may 
contain a wide range of genetic and epigenetic states.37,38 
This intratumoral heterogeneity confounds diagnosis, chal-
lenges the design of effective therapies, and is a determin-
ant of tumor resistance.39 Molecular heterogeneity in GBM 
has been characterized using multiple approaches. For 
example, fluorescent in situ hybridization analysis of the 
most commonly amplified receptor tyrosine kinases (RTKs) 
in GBM (epidermal growth factor receptor [EGFR], platelet 
derived growth factor receptor alpha [PDGFRA], and MET) 
revealed a mosaic of tumor subclones marked by different 
RTK amplifications in 2%–3% of GBM,40,41 possibly indi-
cating cooperation between cell populations. Single-cell 
sequencing demonstrated comparable non-overlapping 
subclonal GBM cell populations marked by different EGFR 
truncation variants, suggesting convergent evolution of 
EGFR mutations.42 Genomic profiling of spatially distinct 
tumor sectors has revealed partial overlap in the mutation 
content in multiple samples from IDH-mutant lower-grade 
glioma17,36,43,44 and IDH-wildtype GBMs.34,35,45–47 Somatic 
mutations/DNA copy number alterations in important gli-
oma driver genes such as TP53 and phosphatase and 
tensin homolog (PTEN) have been found to be subclonal, 
suggesting they were acquired after tumor initiation. These 
unexpected discoveries show the many genetic routes 
tumor cells can take to overcome anti-tumorigenic barri-
ers such as senescence and genomic instability. The pos-
sibility of extrachromosomal oncogene amplification adds 
an additional layer of complexity, allowing tumors to rap-
idly increase intratumoral heterogeneity in response to a 
microenvironment sparse in resources.48–53
Table 1 Summary of cohort based longitudinal characterization of glioma studies
# Publication Journal PMID Year Data Types Glioma Type 
at Diagnosis
Cohort Size
(#patients)
1. Phillips et al15 Cancer Cell 16530701 Mar 2006 Gene expression arrays High grade 23
2. Johnson et al36 Science 24336570 Dec 2013 Exome sequencing Low grade 23
3. Kim et al34 Genome Res 25650244  Feb 2015 Whole genome and exome sequenc-
ing, DNA copy number arrays
Glioblastoma 23¥1
4. Suzuki et al17 Nat Genetics 25848751 Apr 2015 Exome sequencing Low grade 10
5. Kim et al68 Cancer Cell 26373279 Sep 2015 Exome sequencing, array CGH, RNA 
sequencing
Glioblastoma 38
6. Mazor et al43 Cancer Cell 26373278 Sep 2015 DNA methylation, RNA sequencing Low grade 21*1
7. Kwon et al73 PLoS One 26466313 Oct 2015 Gene expression arrays Glioblastoma 15
8. Bai et al44 Nat Genetics 26618343 Nov 2015 Exome sequencing, array CGH, gene 
expression arrays, DNA methylation
Low grade 41
9. Wang et al69 Nat Genetics 27270107 July 2016 Exome sequencing Glioblastoma 39*2
10. DeCarvalho 
et al48
Biorxiv NA Nov 2016 Whole genome sequencing and CGH 
arrays
Glioblastoma 21¥2, *3
11. Wang et al59 Cancer Cell 28697342 June 2017 Gene expression arrays, RNA 
sequencing
Glioblastoma 36¥3, *4
12. Klughammer 
et al79
Biorxiv NA 2017 DNA methylation Glioblastoma 112
13. Ferreira de 
Souze et al78
Biorxiv NA 2017 DNA methylation Low grade 32¥4,*4
*1 Additional characterization on cohort from #2.
*2 Analysis additionally includes data from cohorts in #2, #3, #4, #5.
*3 Analysis additionally includes data from cohorts in #3, #5.
*4 Additional characterization on cohort from #3, includes re-analysis of cohorts from #1, #6, #7.
*5 Analysis additionally includes data from cohorts in #6, #8.
¥1 Including 13 glioma pairs from TCGA.
¥2 Including 14 glioma pairs from TCGA.
¥3 Additional characterization on 27 glioma pairs from TCGA, overlapping with ¥1 and ¥2
¥4 Including 27 glioma pairs from TCGA, overlapping with ¥1 and ¥2
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Intratumoral mutation retention rates may be corre-
lated with the geographical distance between samples in 
the tumor,47 and by extension, the level of heterogeneity 
between different lesions of multifocal GBM is greater than 
between different areas in the same GBM.47,54,55 Spatial het-
erogeneity determined by genetic alterations is reflected in 
the epigenetic patterns of different tumor sections exam-
ined by combined analysis of DNA methylation and gen-
etic abnormalities.43,46 These accumulating data suggest 
that intratumoral heterogeneity is encoded through a gen-
omic–epigenomic codependent relationship,43 in which 
epigenetic changes may modulate mutational susceptibil-
ity in proximal cells, and specific mutations dictate aberrant 
epigenetic patterns.43,56,57 Although gene expression signa-
tures can be used to subclassify GBMs, the predominant 
subtype often varies from region to region within a given 
tumor.35,46 This relative instability may be in part due to the 
variable levels of tumor-associated non-neoplastic cells 
that can be found in different parts of the tumor.58,59 Single-
cell RNA sequencing of GBM cells has shown that glioma 
cells from the same tumor can correspond to different gli-
oma subtypes, often with one dominating the others.47,59–61 
Single-cell transcriptomics extend previous observations 
of mosaic RTK amplification in a small subset of GBM to be 
a more common disease characteristic.60,61 Single-cell RNA 
sequencing further has shown cellular hierarchies along 
an axis of undifferentiated progenitors to more differenti-
ated cell populations, reminiscent of the hematopoietic 
stem cell hierarchy. The balance shifts toward proliferating 
progenitors in IDH-wildtype glioma, reflecting the clinically 
more aggressive disease course.62,63 These developmen-
tal and functional hierarchies are associated with dynamic 
neural stem cell expression patterns in which stem or pro-
genitor cells may function as units of evolutionary selec-
tion (Fig. 2).
Longitudinal DNA Profiling in Pretreatment and 
Posttreatment Tumors
One of the earliest reports on the effects of therapy on the 
tumor genomic landscape analyzed a 23-patient cohort of 
IDH-mutant lower-grade gliomas treated with temozolo-
mide chemo.64 A subset of the recurrent tumors acquired 
hundreds of new mutations that bore a characteristic sig-
nature of temozolomide-induced mutagenesis, suggesting 
that treatment pressure from an alkylating agent induced 
the growth of tumor cells with new mutations.36 These 
Tumor evolution
Origin Diagnosis Recurrence
A single dominant
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Fig. 2 Simplified glioma evolution models. The glioma-initiating cell evolves into the tumor at diagnosis with selective pressures resulting in 
intratumoral heterogeneity. Recurrent tumors share few or the majority of the somatic alterations seen in the diagnostic tumors depending on the 
evolutionary pattern (linear, branching, or ancestral evolutions). Subclones may be marked by mutations or extrachromosomal DNA elements.
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hypermutated tumors may be sensitive to immune check-
point inhibitors,22 including programmed death 1 (PD-1) 
inhibitors65 and poly-adenosine diphosphate ribose poly-
merase inhibitors.66 However, clinical trial data supporting 
these hypotheses have yet to emerge. Another study used 
whole-genome and multisector exome sequencing of 23 
predominantly IDH-wildtype GBM and matched recurrent 
tumors.34 This study showed that some GBM recurrences 
carried ancestral p53 driver mutations detectable in the pri-
mary GBM counterparts, suggesting an intrinsic resistance 
mechanism. Other recurrences were driven by branched 
subclonal mutations not present in the parental primary 
GBM. This may imply secondary or extrinsic resistance, 
reflecting treatment-induced resistance through DNA 
mutagenesis and a distinct evolutionary process (Fig. 2).34 
As in the study of IDH-mutant lower-grade gliomas, a sub-
set of the disease recurrences was characterized by an 
accumulation of mutations in association with temozolo-
mide treatment. Notably, this effect was limited to cases 
with MGMT promoter methylation. MGMT is a gene in 
the DNA repair pathway, and somatic mutations of other 
pathway members, such as mutS homolog 2 (MSH2) and 
MSH6, have been identified as drivers of the hypermuta-
tion process.67 The spatiotemporal evolutionary trajectory 
in paired gliomas between initial diagnosis and relapse 
was further portrayed via integrative genomic and radio-
logic analyses through whole-exome sequencing (WES) of 
38 primary and corresponding recurrent tumors.68 Linear 
evolution, reminiscent of intrinsic resistance in which a 
recurrent tumor is genetically similar to the initial tumor, 
was predominantly observed in recurrent tumors that 
relapsed adjacent to the primary site. Branched evolution, 
associated with secondary or extrinsic resistance, was 
more common in recurrences at distant sites, which were 
marked by a substantial genetic divergence in their muta-
tional profile from the initial tumor, with key driver altera-
tions differing in more than 30% of cases. Geographically 
separated multifocal tumors and/or long-term recurrent 
tumors were seeded by distinct clones, as predicted by an 
evolution model defined as multiverse, ie, driven by mul-
tiple subclonal cell populations.47 In an effort to elucidate 
the diverse evolutionary dynamics by which gliomas are 
initiated and recur, the clonal evolution of GBM under ther-
apy was assessed from an aggregated analysis of datasets 
generated by multiple institutions.69 Systematic review of 
the exome sequences from 93 patients revealed highly 
branched evolutionary patterns involving a Darwinian pro-
cess of clonal replacement in which a subset of clones with 
a selective advantage during a standard treatment regi-
men renders the tumor susceptible to disease progression 
(Fig. 2). Mathematical modeling delineated the sequential 
order of somatic mutational events that constitute GBM 
genome architecture, identifying somatic mutations in 
IDH1, phosphatidylinositol-4,5-bisphosphate 3-kinase cata-
lytic subunit alpha (PIK3CA), and ATRX as early events of 
tumor progression, whereas PTEN, neurofibromatosis 
type 1 (NF1), and EGFR alterations were predicted to occur 
at a later stage of the evolution.47 Similar observations 
have been reported from studies of low-grade gliomas, 
demonstrating that the somatic mutations in IDH1, TP53, 
and ATRX were frequently early and retained throughout 
tumor progression from primary to relapse.17,44
Longitudinal profiling of paired samples continues to 
provide deeper insights into the genomic background 
of treatment-induced hypermutagenesis. The latter has 
potential to increase aggressive clinical behavior and rele-
vance in targeted and immunotherapy.17,44,70,71 The impli-
cations of these pilot data and how these insights can be 
integrated into clinical practice require further evaluation. 
Collectively, longitudinal genomic profiling will be essen-
tial in implementing clinical application toward patient-tai-
lored treatment regimens.
Transcriptional Changes During Glioma 
Progression
Unsupervised transcriptome analysis of GBM converged 
on 4 expression subtypes, referred to as classical, mesen-
chymal, neural, and proneural, which are associated with 
specific genomic abnormalities.12,14,15,72
Transcriptional subtypes of the relatively homogeneous 
IDH-mutant and IDH-mutant 1p/19q-codeleted groups have 
been less emphasized in the literature, as these cases usu-
ally carry a proneural signature.10,12 While expression sub-
type classification is a widely used research tool, it has not 
been shown to correlate with clinical outcome, and has not 
been incorporated in the recent 2016 WHO CNS tumor clas-
sification update. Much is still unknown about how tran-
scriptional subclasses evolve under therapy. A switch from 
proneural to mesenchymal expression has been observed 
upon disease recurrence and was proposed to be a source 
of treatment resistance in GBM relapse,15,73,74 but the rele-
vance of this phenomenon in glioma progression remains 
ambiguous, particularly considering (i) the increased frac-
tion of microglial/macrophage cells in mesenchymal GBM 
that confound subtype characterization58,59 and (ii) glioma 
neurospheres derived from mesenchymal GBM that are 
frequently classified as proneural.74 Deriving an expres-
sion subtype classification on the basis of glioma-intrinsic 
genes has maintained the proneural, classical, and mesen-
chymal classes.59 Determining subtypes in a cohort of 91 
IDH-wildtype GBM showed subtype switching following 
therapy and disease relapse in 45% of the cohort.59 These 
patterns converged with changes in the microenvironment 
but also revealed that NF1 loss results in macrophage/
microglia recruitment. The ability of genomic abnormali-
ties to regulate the tumor microenvironment shows how 
tumors act as a system, rather than an aggregation of indi-
vidual cells.
Epigenetic Changes During Glioma Progression
DNA methylation profiling of gliomas has prognostic value 
independent of patient age and the pathologic grade of 
the tumor.9 Evidence suggests that evolutionary selection 
can also act on the epigenome, affording cells plasticity 
to resist therapy.9,43 For example, recurrent IDH-mutant 
gliomas profiled for mutations and DNA methylation inde-
pendently evolved deregulation of their cell cycle programs 
through genetic mutations or epigenetic mechanisms.43
Nearly all IDH-mutant gliomas exhibit a characteris-
tic cytosine-phosphate-guanine island hypermethylator 
phenotype (G-CIMP), which (i) induces silencing of key 
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extracellular matrix and cell migration gene promoters,10 
(ii) mediates alteration of chromosome topography, lead-
ing to oncogene upregulation,75,76 (iii) mediates histone 
methylation-related changes in gene expression, and (iv) 
may play a role in creating an immunosuppressed micro-
environment.77 While almost all IDH-mutant tumors are 
G-CIMP at diagnosis, a longitudinal analysis showed that 
34% of cases exhibited demethylation toward G-CIMP–
intermediate or G-CIMP–low DNA methylation at recur-
rence.78 Substantial epigenetic heterogeneity between 
tumor samples from the same patient collected at subse-
quent surgeries was also observed in a cohort of 112 pri-
mary mostly non–G-CIMP GBM patients.79 Characteristic 
trends in DNA methylation between primary and relapsed 
GBM included a prominent demethylation of gene promot-
ers related to Wnt signaling, which was associated with 
worse patient outcome. Moreover, patients whose primary 
tumors harbored higher levels of DNA methylation het-
erogeneity showed longer progression-free survival and a 
trend toward longer overall survival.79
Imaging and (Epi)genomics
MRI is noninvasive, with no risk of radiation exposure. 
Standard MRI includes precontrast and postcontrast 
T1-weighted (T1w) and T2-weighted (T2w)/T2w fluid-
attenuated inversion recovery (T2-FLAIR) imaging assess-
ing tumor location, size, and other features.80 Newer 
techniques such as perfusion imaging provide a measure 
of tumor vascularization in terms of relative cerebral blood 
volume, which correlates with tumor grade.81,82 There is 
interest in exploring the relationships between MR findings 
such as cerebral blood volume with the biological behavior 
of tumors—for example, to determine risk prior to surgery.
In the rapidly growing field called radiogenomics,83 
quantitative imaging features can be linked with genomic 
profiles, with recent applications in high-grade glioma.83,84 
A priority of radiogenomics is to identify MRI-based bio-
markers for glioma subtypes such as IDH-mutant versus 
wildtype and 1p/19q codeleted versus non-codeleted. 
Noninvasive phenotypic assessment provides an early 
test to stratify IDH-mutant non-codeleted gliomas and may 
offer prognostic information through MRI with the poten-
tial to influence patient outcomes and determine risk prior 
to surgery.85 It may also help in selecting personalized 
treatments in clinical trials.86 A detailed global assessment 
of the spatial and longitudinal heterogeneity of gliomas is 
potentially feasible.87
Barriers to Progress
The major obstacle for glioma patients is a lack of effective 
treatments, which may result from cell-intrinsic resistance 
or treatment-resistant glioma cells being favored over treat-
ment-sensitive cells, augmented or attenuated by micro-
environmental influences, including hypoxia and stromal 
elements. That therapy has profound effects on tumor 
composition is reflected by the temozolomide-induced 
hypermutator phenotype.64 As a result, the molecular char-
acteristics of the recurrent tumor differ in significant ways 
from those found in the primary tumor.34,36 TCGA and simi-
lar initiatives elsewhere have established comprehensive 
portraits of the interpatient variability of untreated glioma 
genomes. Single-cell sequencing and barcoding experi-
ments have demonstrated functional hierarchies providing 
important insights into characteristics of the most relevant 
cells to target.62,63 We are increasingly able to infer the life 
history of glioma,33 from germline predispositions88,89 and 
tumor-initiating events such as IDH1 mutation to tumor-
promoting events such as RTK alterations. To improve the 
outcomes of patients with gliomas, we need to establish a 
thorough understanding of the treatment-induced molecu-
lar and genetic diversity that leads to resistance.
A detailed understanding of the biological diversity 
within every tumor following clinical presentation and 
disease progression is needed if we are to successfully 
understand how treatment affects glioma progression. 
This is an essential step toward the integration of precision 
therapeutics into clinical decision making, highlighting the 
danger in considering treatment options for patients with 
recurrent tumors solely on the basis of the molecular ana-
lysis of their treatment-naïve tumors. This is particularly 
important in the setting of clinical research, which often 
recruits patients with recurrent GBM to evaluate drugs 
developed on the basis of mechanistic data obtained on 
treatment-naïve tumors.
Studying the heterogeneity and spatiotemporal evolu-
tion of cancer in general, and particularly in brain cancer, 
is challenging. Many tumor samples—and therefore large-
scale collaboration—are needed to achieve meaning-
ful comprehensive results and to capture low-frequency 
alterations or subtle therapy-driving processes. Individual 
research groups typically do not have the resources to use 
a multiplatform analysis of their samples, owing to cost or 
the availability of expertise. Published longitudinal datasets 
consist of a mixture of different modalities, ranging from 
only exomes36 or DNA methylation profiles43,79 to a com-
bination of exome sequencing, RNA sequencing, and DNA 
copy number profiling,34,59 thwarting meta-analyses based 
on cross-publication comparisons. The value of establish-
ing a comprehensive multiplatform reference dataset 
quickly has been demonstrated by the success of TCGA, 
the International Cancer Genomics Consortium (ICGC), the 
Therapeutically Applicable Research to Generate Effective 
Treatments (TARGET) Consortium, and other glioma pro-
jects, which have led to a fundamental reclassification of gli-
omas by the WHO19 and are highly cited.8,10–12,90,91 Similarly, 
a consortium would be the most effective approach to 
assemble the large cohorts of primary and recurrent tumor 
pairs needed to identify somatic alterations enriched after 
disease progression. Systematizing and standardizing what 
we do and how we do it will be essential for change to clini-
cal practice in neuro-oncology. This philosophy is at the 
core of the international GLASS Consortium.
The Glioma Longitudinal Analysis 
(GLASS) Consortium
Large-scale collaborations are needed to help us under-
stand the impact of treatment on evolutionary dynamics 
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and thereby develop novel treatments to prevent and over-
come resistance to treatment. GLASS aims to perform com-
prehensive molecular profiling of matched primary and 
recurrent glioma specimens from 1500 patients, 500 in each 
of the 3 major glioma molecular subtypes. At the time of 
writing, the consortium includes investigators from 34 aca-
demic hospitals, universities, and research institutes from 
12 countries (see list of participants on the GLASS website, 
http://www.glass-consortium.org). By analogy with the 
ICGC,90 GLASS is structured into country-specific franchises 
(GLASS-NL, GLASS-AT, GLASS-AU, GLASS-Korea, etc) led 
by local investigators who are invested in the team’s over-
all goal, while taking advantage of country-specific oppor-
tunities. This enables each GLASS branch to have unique 
features that allow a deeper analysis of subcohorts, that is, 
with additional imaging annotation, parallel characterization 
of drug response through xenografting of tumor samples, 
autopsies, a specific focus on a glioma subtype, etc, thereby 
making them competitive and enabling them to address 
non-overlapping aspects of the phenotypic diversity seen 
in the clinic. Country-specific branches will be coordinated 
to connect with the larger analyses and to drive specific 
research topics for both. There are no explicit restrictions on 
publishing, and each group is invited to publish their sub-
studies independently. The overall goal is to establish a ref-
erence dataset by pooling samples and aggregate data from 
all multiplatform analyses, countries, and substudies, and 
to make datasets comparable through coordinated sam-
ple and data processing guidelines. Country franchises are 
centrally connected through a number of committees, each 
overseeing different aspects of the analysis.
Biospecimen Acquisition and Characterization 
Platforms
Biospecimens from gliomas are often snap-frozen or con-
served as formalin-fixed, paraffin-embedded (FFPE) sam-
ples. For genomic and transcriptomic analyses, snap-frozen 
material is preferred, while historically FFPE is the com-
mon approach to tissue preservation. Methods for gener-
ating sequencing data from FFPE material are increasingly 
improving, with 5%–20% of samples failing quality controls. 
Given that samples from multiple timepoints are required 
for inclusion into GLASS, patients for whom only FFPE 
material is available are twice as likely to not yield sufficient 
high-quality DNA. While the increased failure rate means 
we will have to include a higher number of samples, we do 
not see this as prohibitive and are actively pursuing the use 
of FFPE material. RNA extracted from glioma tissue is often 
highly degraded, resulting in higher attrition rates,92 but 
high-quality RNA sequencing data from FFPE samples have 
been reported.93 For DNA methylation profiling of FFPE 
material, a recent study focusing on primary glioblastoma 
reported a high success rate using the reduced representa-
tion bisulfite sequencing assay.79
While we require the availability of a matching germline 
sample (blood or other) for inclusion of DNA sequencing 
data into GLASS, cases without a germline match may be 
candidates for transcriptome and DNA methylation analy-
sis. Ideally, we aim to generate DNA, RNA, and epigenomic 
sequencing data from every tumor. Single-cell analysis 
methods require fresh tissue from which individual cells 
can be dissociated; this may be considered in the future 
as the project evolves or as part of specific subprojects. 
Similarly, subsets of the GLASS cohort will be compared 
longitudinally by spatial correlation using multisector anal-
ysis (3–6 samples per tumor) to understand whether any 
differences between paired tumor samples are the result of 
intratumoral heterogeneity or longitudinal heterogeneity. 
Where available, these will be correlated with conventional 
and novel MR imaging to explore spatiotemporal heteroge-
neity noninvasively. We aim to take current radiogenomic 
approaches further, not only to establish the features of 
genetic characteristics at first diagnosis, but also in relation 
to molecular alterations over time and under the pressure 
of standard therapy. Comprehensive genomic sequencing 
is needed to identify patterns of disease evolution as well 
as the key mutations and chromosomal alterations that 
confer resistance to standard radiation, temozolomide, 
and novel clinical trial therapies. Sequencing paradigms 
and their costs are rapidly evolving, and each method pro-
vides different but complementary information. There is no 
consensus on optimal methods. With the accessibility of 
30x coverage whole-genome sequencing (WGS) at $1100 
per biospecimen, the costs of WGS and WES have become 
comparable. The coverage of a typical WES is between 
60x and 100x, which enables greater sensitivity in detect-
ing mutations in coding regions, but WES does not inter-
rogate noncoding regions of the genome and is not able 
to detect structural variants or noncoding copy number 
variants. The comprehensive nature of WGS enables anal-
ysis of evolution and clonality at higher resolution. WGS 
and WES combined may provide the optimal window on 
the breadth, depth, and allelic fraction of somatic events. 
However, where limitations in tissue or resources mandate 
a choice of one or the other, the decision will depend on 
the purpose of the (sub)project. GLASS franchises with a 
focus on clinical relevance may lean toward WES, while 
projects aiming to define clonal relationships may opt to 
perform WGS.
Targeted sequencing data analysis in the absence of a 
matching germline sample is frequently performed in the 
clinical setting, and such datasets, which are typically able 
to provide mutation calls on 20–400 genes, may therefore 
be easily accessible. While GLASS does not intend to pur-
sue generating such datasets, aggregating information 
from existing resources may be a viable option to learn or 
validate mutations enriched at diagnosis or recurrence.
Clinical Annotation in GLASS
Aggregating clinical annotation across the consortium 
will help enable linkage of genotype with clinical and mor-
phological phenotype in primary and recurrent settings. 
The number of clinical annotation elements will be differ-
ent in each country with minimal requirements (Box 1). 
The GLASS clinical annotation committee will standardize 
clinical and imaging data collection for prospective stud-
ies and oversee collection of the clinical and imaging data 
from patients whose profiles are already included in the 
composite dataset. Each individual franchise will make 
data accessible in a comprehensible way by integrating 
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clinical, imaging, and molecular parameters to explore 
correlation with relapse data. Currently, radiology and 
imaging are part of the clinical annotation committee. By 
mapping imaging features in a voxel-wise manner and cor-
relating these spatially with molecular alterations obtained 
from different parts of the tumor, we aim to assess the 
entire tumor and to determine intratumoral heterogeneity.
Data Infrastructure
A designated committee will maintain standardized data 
processing, data management, and data sharing. A charac-
teristic of the GLASS Consortium is that data will be gen-
erated at multiple institutions distributed over multiple 
countries. As the regulations pertaining to ethical use of 
sequencing datasets are continuously evolving, GLASS will 
follow the example set by ICGC to perform decentralized 
data analysis to avoid cross-border exchange of patient-
sensitive raw sequencing data. Batch effects may arise from 
varying library preparations, analyzing fresh-frozen versus 
FFPE tissue, sequencing platforms, laboratories, etc. Batch 
effects are most perturbing when performing unsupervised 
analysis, such as unsupervised clustering from expression 
or DNA methylation profiles. Adequately correcting for 
these items will be necessary to obtain usable data.
The GLASS data infrastructure committee has developed 
Docker software images that are shared among participating 
institutions and that enable analysis uniformity. Like a ship-
ping container, a Docker image packages one or more soft-
ware tools to establish a workflow resembling an executable 
application. Comparable to platform-independent Java soft-
ware, the ready-to-run Docker images are independent of 
the local computational environment. Along the same lines, 
comparable Singularity images have been prepared. The 
GLASS participants run these images locally, which initial-
izes a per-sample-per-analysis Docker/Singularity container, 
resulting in data analysis using an identical software envir-
onment and run parameters. Docker/Singularity images and 
documentation are available for download through http://
docker.glass-consortium.org.
The data infrastructure committee will also coordinate 
mechanisms for dissemination of results, so as to widely 
share datasets with the community. We may explore mech-
anisms such as the Genomic Data Commons, or similar, to 
align our efforts with other molecular profiling studies.
Box 1. GLASS aims to collect genome-wide DNA, RNA, and epigenomic sequencing data on 1500 glioma tissues and 
matched recurrent tissues. To be included in this core set of cases, tissues and germline reference are required, with 
a minimal clinical dataset. Submission of standard cases without a germline source or without complete molecular 
profiling is encouraged. To generate a comprehensive data resource for the molecular study of glioma recurrence, 
cases with molecular data on matched primary/recurrent specimens will be collected into an archive.
¥ All data should be provided in compliance with HIPAA regulations, ie, dates as intervals.
CORE CASE REQUIREMENTS
• Primary diagnosis of glioma (WHO Grade II-IV) with frozen/FFPE tumor specimen
• Matched recurrent diagnosis of glioma (WHO Grade II-IV) with frozen/FFPE tumor specimen
• Matched germline reference specimen
OR
• Global DNA sequencing (WES or WGS) on matched glioma pairs (Grade II-IV primary) and 
germline reference specimen and RNA sequence and DNA methylation on matched glioma
pairs (Grade II-IV primary) 
WITH
• Clinical data: age at diagnosis, year of diagnosis, time from diagnosis to recurrence, treatment 
history between diagnoses¥
STANDARD CASE REQUIREMENTS
• Primary diagnosis of glioma (WHO Grade II-IV) with frozen/FFPE tumor specimen
• Matched recurrent diagnosis of glioma (WHO Grade II-IV) with frozen/FFPE tumor specimen
OR
• Global DNA sequencing (WES or WGS) on matched glioma pairs (Grade II-IV primary) and 
germline reference specimen and/or RNA sequence and/or DNA methylation on matched 
glioma pairs (Grade II-IV primary) 
WITH
• Clinical data: age at diagnosis, year of diagnosis, time from diagnosis to recurrence,
treatment history between diagnoses¥ 
• IDH mutation and 1p/19q co-deletion status if DNA sequence is not available
ARCHIVE CASE REQUIREMENTS
• Molecular data on primary/recurrent matched glioma specimens
WITH
• Clinical data: age at diagnosis, year of diagnosis, time from diagnosis to recurrence¥
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Final Remarks and Perspectives
Survival and quality of life for patients with diffuse glio-
mas remain dismal with standard treatments. Diffuse 
glioma is a fatal disease with an enormous societal bur-
den as a result of the short survival following high-grade 
disease and the young age at diagnosis of lower-grade 
disease. This not only affects patients in the prime of their 
lives, but also puts enormous burden on their immediate 
entourage, as they need extensive supportive care and 
navigation through a complicated medical landscape, 
and experience difficulties with medical costs and insur-
ance. While cures of diffuse gliomas remain elusive, our 
patients demand better therapies. With no substantive 
impact of molecular medicine to date, in practice treat-
ments remain “one size fits all.” The GLASS Consortium 
aims to improve clinical outcomes by establishing a 
broadly useful dataset that will provide pivotal new 
insights into the mechanisms used by gliomas to defy 
therapeutic challenges.
Importantly, GLASS is also an opportunity for the 
exchange of knowledge among an international group of 
collaborators to ultimately build smarter clinical trials and 
develop therapies that will extend survival and improve the 
quality of life of people with diffuse gliomas. GLASS is well 
positioned to demonstrate the value of well-coordinated 
collaborative efforts. To that end, new investigators are 
invited to join the consortium, where the major criteria for 
participation are the ability to offer datasets of longitudi-
nally profiled glioma patients or the availability of suitable 
tissue samples.
In summary, through the GLASS Consortium, we aspire 
to continue the immeasurable success of TCGA while 
increasing the focus on making a difference to patients and 
their families.
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